Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2820-2823

  Cheng, Liang ^a   Pisansky, Thomas M ^b   Sebo, Thomas J ^b   Leibovich, Bradley C ^b   Ramnani, Dharamdas M ^b   Weaver, Amy L ^b   Scherer, Beth G ^b   Blute, Michael L ^b   Zincke, Horst ^b   Bostwick, David G ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c BOSTWICK LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CELL PROLIFERATION; HUMAN; IMAGE ANALYSIS; LABELING INDEX; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RADIOGRAPHY; TUMOR BIOPSY;

AGED; CELL DIVISION; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0032742243     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Cheng, L., Bergstralh, E. H., Cheville, J. C., Slezak, J., Corica, F. A., Zincke, H., Blute, M. L., and Bostwick, D. G. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol., 22: 1491-1500, 1998.
3. Zincke, H., Bergstralh, E. J., Larson-Keller, J. J., Farrow, G. M., Myers, R. P., Lieber, M. M., Barrett, D. M., Rife, C. C., and Gonchoroff, N. J. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer (Phila.), 70: 311-323, 1992.
4. Millikan, R., and Logothetis, C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology, 11: 180-193, 1997.
5. Lawton, C. A., Winter, K., and Byhardt, R. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate: results based on a national prospective randomized trials, RTOG 85-31. Int. J. Radiol. Oncol. Biol. Phys., 38: 931-939, 1997.
6. Myers, R. P., Larson-Keller, J. J., Bergstralh, E. J., Zincke, H., Oesterling, J. E., and Lieber, M. M. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J. Urol., 147: 910-915, 1992.
7. Zincke, H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology, 33: 27-36, 1989.
8. Cheng, C. W., Bergstralh, E. J., and Zincke, H. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer, 71: 996-1004, 1993.
9. Ghavamian, R., Bergstralh, E. J., Blute, M. L., Slezak, J., and Zincke, H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J. Urol., 161: 1223-1228, 1999.
10. Seay, T. M., Blute, M. L., and Zincke, H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J. Urol., 159: 357-364, 1998.
11. Cheng, L., Slezak, J., Bergstralh, E. J., Cheville, J. C., Sweat, S., Zincke, H., and Bostwick, D. G. Dedifferentiation in metastatic progression of prostate cancer, Cancer, 86: 657-663, 1999.
12. Cheng, L., Leibovich, B. C., Bergstralh, E. J., Scherer, B. G., Pacelli, A., Ramnani, D. M., Zincke, H., and Bostwick, D. G. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer, 85: 2455-2459, 1999.
13. Cheng, L., Bostwick, D. G., Li, G., Wang, Q., Hu, N., Vortmeyer, A. O., and Zhuang, Z. Allelic imbalance in the clonal evolution of prostate cancer. Cancer, 85: 2017-2022, 1999.
14. Fleming, I. D., Cooper, J. S., Henson, D. E., Hutter, R. V. P., Kennedy, B. J., Murphy, G. P., O'Sullivan, B., Sobin, L. H., and Yarbro, J. W. AJCC Cancer Staging Manual, pp. 241-246. Philadelphia: Raven and Lippincott, 1997.
15. Bostwick, D. G. Neoplasms of the prostate. In: D. G. Bostwick and J. N. Eble (eds.), Urologic Surgical Pathology, pp. 343-422. St. Louis: Mosby, 1997.
16. Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rugg, C. A., and Musgrove, E. A. Method for analysis of cellular content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333-1335, 1983.
17. Cheng, L., Sebo, T. J., Slezak, J., Pisansky, T. M., Bergstralh, E. J., Neumann, R. M., Iczkowski, K. A., Zincke, H., and Bostwick, D. G. Predictors of survival in prostate cancer patients treated with salvage radical prostatectomy after radiation therapy. Cancer, 83: 2164-2171, 1998.
18. Altman, D. G., Lausen, B., Sauerbrei, W., and Schumacher, M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J. Natl. Cancer Inst., 86: 829-835, 1994.
19. Cher, M. L., Stephenson, R. A., James, B. C., and Carroll, P. R. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+MO) prostate cancer. J. Urol., 155: 1674-1677, 1996.
20. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., and Moul, J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511-1516, 1996.
21. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C., and Mihatsch, M. J. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol., 148: 1557-1565, 1996.
22. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
23. Colombel, M., Olsson, C. A., Ng, P. Y., and Buttyan, R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res., 52: 4313-4319, 1992.
24. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143: 390-400, 1993.
25. Eisenberger, M. A., and Nelson, W. G. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J. Natl. Cancer Inst., 88: 779-781, 1996.
26. Schellhammer, P., Cockett, A., Boccon-Gibod, L., Gospodarowicz, M., Krongrad, A., Thompson, I. M., Scardino, P., Soloway, M., and Adolfsson, J. Assessment of endpoints for clinical trials for localized prostate cancer. Urology, 49: 27-38, 1997.